Tuesday, June 11, 2019

Daily Update - Tuesday June 11th, 2019

Regulatory -

FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma
- FDA grants accelerated approval of Polivy to Genentech.  One more approval is always a good day for ADCs in general

Manuscripts -

A Physical Organic Approach to Tuning Reagents for Selective and Stable Methionine Bioconjugation
- Cysteine conjugation is now well established for ADCs but can methionines be used to accomplish site-specific conjugation as well.  Look out THIOmab

Boronic acids as building blocks for the construction of therapeutically useful bioconjugates
Royal Society of Chemistry
- A nice review article about using boronic acids to find new bioconjugate targets

Considerations for the Design of Antibody-Based Therapeutics
Journal of Pharmaceutical Sciences
- Its easy to forget that every ADC is based on the mAb.  This is a nice review about the challenges and intricacies of mAb engineering

Clinical Results -

Positive results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Biospectrum Asia
- Phase II clincal results showing that HER2 is not limited to breast cancer.  IND to be filed later this year

Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me. [email protected]

No comments:

Post a Comment